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a b s t r a c t
Background: Migraine is a common comorbidity among individuals with bipolar disorder, but the
underlying mechanisms for this co-occurrence are poorly understood. The aim of this study was to
investigate the genetic background of bipolar patients with and without migraine.
Methods: We performed a genome-wide association analysis contrasting 460 bipolar migraneurs with
914 bipolar patients without migraine from the Bipolar Genome Study (BiGS).
Results: We identiﬁed one genome-wide signiﬁcant association between migraine in bipolar disorder
patients and rs1160720, an intronic single nucleotide polymorphism (SNP) in the NBEA gene
(P¼2.97108, OR: 1.82, 95% CI: 1.47–2.25), although this was not replicated in a smaller sample of
289 migraine cases.
Limitations: Our study is based on self-reported migraine.
Conclusions: NBEA encodes neurobeachin, a scaffolding protein primarily expressed in the brain and
involved in trafﬁcking of vesicles containing neurotransmitter receptors. This locus has not previously
been implicated in migraine per se. We found no evidence of association in data from the GWAS migraine
meta-analysis consortium (n¼118,710 participants) suggesting that the association might be speciﬁc to
migraine co-morbid with bipolar disorder.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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1. Introduction
Migraine is a common neurological disorder, affecting approxi-
mately 12–15% of populations of European ancestry and costing
close to $ 20 billion in the United States and € 27 billion in Europe
each year (Andlin Sobocki et al., 2005; Holland et al., 2012). Among
neurological disorders, it accounts for the greatest number of years
lived with disability (YLDs), ranking eighth among all human
disorders (Vos et al., 2012). Migraine is 3–4 times more common
in women, and its estimated heritability is between 40% and 65%
(Anttila et al., 2008; Holland et al., 2012; Schürks et al., 2010). The
diagnosis of common migraine includes recurrent attacks of
disabling unilateral headaches along with nausea, vomiting,
photo- and phonophobia, and about 20–30% have accompanying
aura symptoms (Freilinger et al., 2012; Holland et al., 2012).
Mendelian forms of familial hemiplegic migraine (FHM) are
rare. Most are caused by mutations in the CACNA1A, ATP1A2 and
SCN1A genes (Di Lorenzo et al., 2012). Non-familial migraine is
perceived to be polygenic, with considerable diversity regarding
both the number as well as the severity and duration of attacks
(Maher and Grifﬁths, 2011). Linkage and candidate gene studies of
non-familial migraine have yielded few replicable results.
Recently, genome wide association studies (GWAS) have provided
new insights into the disorder, with several associated genes such
as the ion channel gene TRPM8 (Chasman et al., 2011; Di Lorenzo
et al., 2012; Freilinger et al., 2012; Maher and Grifﬁths, 2011), as
well as FHL5, ASTN2 and LRP1 (Anttila et al., 2013).
Bipolar disorder (BPD) has a prevalence of about 1% and a
heritability close to 60% (Oedegaard et al., 2010). BPD has a high
socioeconomic impact and is the sixth most common cause of
YLDs within neurological disorders (Vos et al., 2012). Sufferers of
BPD experience periods of elevated and lowered mood in a cyclic
pattern, sometimes peaking in full-blown mania and psychosis or
severe depression (Chen et al., 2013; Holland and Agius, 2011; Lee
et al., 2012). A comprehensive meta-analysis of candidate gene
studies in BPD by Seifuddin et al. (2012) did not conﬁrm consistent
association with any of the genes examined. GWAS analyses of BPD
have pointed to CACNA1C, ZNF804A, NCAN, ODZ and ANK3 as strong
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candidates, with replication across several studies (Green et al.,
2012; Lee et al., 2012; Offord, 2012). In addition, numerous other
genes have also been found to be signiﬁcant in one of the studies
of BPD, but, so far, failed to replicate (Green et al., 2012; Lee et al.,
2012; Offord, 2012).
Both clinical and population based studies have shown that the
prevalence of migraine in patients with BPD is 2–3 times higher
than in the overall population (Dilsaver et al., 2009; Hirschfeld et
al., 2003; McIntyre et al., 2006). It has also been noted that
migraine attacks are more frequent in sufferers of BPD compared
to those of unipolar depression (Fasmer, 2001). In addition, BPD
patients with migraine have earlier onset of bipolar symptoms,
more comorbid anxiety, greater use of medical services, more
medications and disability payments, and a lower rating of
subjective health compared to bipolar patients without migraine
(Mahmood et al., 1999; McIntyre et al., 2006). Both migraine and
BPD can evolve from irregular occurrences into a drug resistant,
more constant disorder, namely transformed migraine and rapid
cycling BPD (Low et al., 2003). In addition, anti-epileptic drugs,
such as valproate, are used to treat both migraine and BPD
(Oedegaard et al., 2010); and both disorders have been linked to
genes encoding ion channels in the serotonergic and glutamatergic
neurotransmitter systems, including voltage gated calcium chan-
nels (Anttila et al., 2010; Freilinger et al., 2012; Oedegaard et al.,
2010). These strong links between migraine and bipolar disorder,
suggest either common etiology or co-morbid migraine as a sub-
phenotype of bipolar disorder.
In this study, we aimed to search for genetic variants associated
with increased risk for migraine in individuals with BPD through
genome wide association analyses.
2. Materials and methods
2.1. Subjects
Subjects for this study were derived from the Bipolar Genetics
Study (BiGS) Consortium, collected as wave 5 of the National
Institute of Mental Health (NIMH) Genetics Initiative for Bipolar
Disorder. Wave 5 consists of bipolar I singletons and healthy
controls genotyped in two phases by the Translational Genomics
Institute (TGEN): TGEN1 and TGEN2. All bipolar patients were
interviewed using the Diagnostic Interview for Genetic Studies
(DIGS), which included questions regarding migraine. Questions
about aura symptoms were not included in the DIGS. Controls for
the BiGS, which were ascertained through a separate recruitment
effort, did not answer these questions about migraine, and, thus,
were excluded from association analyses (Sanders et al., 2010). The
recruitment process and interviews are described in more detail
by Greenwood and Kelsoe, 2013. Replication was attempted in the
bipolar I sample that was genotyped as part of the Genetics
Association Information Network (GAIN), and a part of the overall
BiGS sample. All subjects were of European descent. Written
informed consent was obtained for each subject following a
detailed description of study participation in accordance with
local Institutional Review Board protocols.
2.2. Genotyping and quality control
All subjects in both TGEN and GAIN were genotyped on the
Affymetrix Genome-Wide Human SNP array 6.0 chip (Affymetrix
Inc., Santa Clara, CA, USA), using the standard protocol. For details,
see the two papers by Smith et al. 2009; 2011. Quality control (QC)
thresholds were set to exclude individuals with4 5% failed
genotypes and markers with less than 95% genotyping rate, minor
allele frequency (MAF) below 1% and out of Hardy–Weinberg
Equilibrium (P-valueo0.0001). In addition, individuals displaying
heterozygosity rate outside the range of three standard deviations
of the mean were also excluded. Identity by state (IBS) was used to
identify cryptic relatedness. An X chromosome inbreeding esti-
mate was applied to conﬁrm gender. Genetic homogeneity of the
sample was assured by multidimensional scaling (MDS). We did
not ﬁnd any batch effects between TGEN1 and TGEN2 when
comparing the ﬁrst three MDS components using a t-test, this is
also shown in the three dimensional MDS-plot (Supplementary
Fig. 1). Thus TGEN1 and TGEN2 were pooled for quality control
analyses; GAIN was screened separately, except for identiﬁcation
of cryptic relatedness, which was done across all datasets com-
bined. All genotype analyses were performed in PLINK version 1.07
(Purcell et al., 2007).
2.3. Statistical analyses and imputation
Genome-wide association was tested using logistic regression
with an additive genetic model implemented in PLINK, with and
without gender as a covariate. Manhattan-plots, MDS-plots and
QQ-plots were generated in R-software (http://www.R-project.
org). A genome wide signiﬁcance level of 5108 was chosen in
accordance with recommended general GWAS signiﬁcance thresh-
olds and speciﬁc thresholds for the Affymetrix 6.0 chip (Dudbridge
and Gusnanto, 2008; Li et al., 2012). Power calculations were done
using the Genetic Power Calculator (Purcell et al., 2003). Imputa-
tion and statistical analyses of the top locus on chromosome 13
were performed using Impute2, GTOOL and PLINK, based on
HapMap build 36 data (Freeman and Marchini, 2007; Howie et
al., 2009; International HapMap Consortium, 2003). We applied
the recommended cut-off for the ‘info’ conﬁdence measure (0.3)
and the default cut-off settings for the genotype probability (0.9)
in Impute2 and GTOOL, and used the same model of logistic
regression in PLINK as for the main analysis to assess association
between migraine and the imputed SNPs. As the results showed
no genomic inﬂation (λ¼1.00), we did not use any MDS-
components in the regression analyses.
2.4. Replication in the GAIN sample
The GAIN sample, which is further described in our previous
paper, contains information about both self-reported migraine and
doctor-diagnosed migraine (Oedegaard et al., 2010). Doctor-
diagnosed migraine phenotype was not available in the discovery
TGEN sample; thus, self-reported migraine was used for replica-
tion. Logistic regression analysis of rs1160720 was performed in
the same manner as in TGEN.
2.5. Evaluation of NBEA region in the international headache
genetics consortium (IHGC) sample
In order to evaluate the possible role of NBEA in migraine, and
whether its association is more pronounced in migraine co-
morbid with BPD or migraine in itself, we selected all genotyped
and imputed SNPs with Po104 in the 5 Mb NBEA region and
tested them in the GWAS meta-analysis of International Headache
Genetics Consortium (IHGC) which included 23,285 migraine
patients and 95,425 controls (Anttila et al., 2013). Association of
rs1160720 only was examined in all migraine cases as well as
subgroups of migraine with and without aura. Data on bipolar co-
morbidity was not available for this dataset.
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3. Results
3.1. Initial discovery set: TGEN
In total, 1411 bipolar disorder patients were available for the
analyses. After excluding 15 heterozygosity outliers and 22 sub-
jects due to cryptic relatedness, association was tested in a total of
460 bipolar migraineurs (migþ) and 914 bipolar patients without
migraine (mig). All individuals reported European–American
ethnicity and there were no outliers in MDS analyses. There was
a lower percentage of males among migþ (23%) compared to
mig (41%).
Overall, 723,224 SNPs remained for analyses after excluding
587 SNPs that failed HWE test and 182,789 with low genotyping
rate or MAF below 1%. A QQ plot shows an excess of strong
associations, without any genomic inﬂation (Fig. 1).
Fig. 2 shows the Manhattan plot of our results. All loci with P-
value less than 1104 are reported in Table 1. We found one
genome-wide signiﬁcant SNP, rs1160720 (P¼2.97108,
OR¼1.82, 95% conﬁdence interval (CI)¼1.47–2.25) in the
Neurobeachin (NBEA) gene on chromosome 13 (Fig. 3). The results
remained similar, albeit slightly weaker, when gender was
included as a covariate in the model (OR¼1.76, 95% CI¼1.42–
2.18, P¼2.5107). Gender stratiﬁed analyses showed that the
size and direction of effect were similar between males and
females, with P-value of 2.77106 (OR¼1.81, 95% CI¼1.41–
2.33) in women compared to P-value of 0.03 (OR¼1.61, 95%
CI¼1.05–2.48) in men.
3.2. Replication in a second bipolar sample: GAIN
After QC, the GAIN sample consisted of 289 migþ and
697 mig individuals with bipolar disorder. This resulted in
approximately 80% power to nominally detect an OR41.3 from
the primary study, given a minor allele frequency of 0.2. We found
no evidence of an association between rs1160720 and self-
reported migraine in this sample of bipolar patients (OR¼0.93,
95% CI¼0.72–1.20, P¼0.57).
3.3. Imputation of top locus
Imputation of the region spanning from 32 to 37 Mbp for the
chromosome 13 NBEA locus resulted in a total of 1618 imputed
SNPs with 98.3% overall concordance cross validation. Fig. 3
illustrates the results from the candidate region on chromosome
13 after imputation. One imputed SNP showed a marginally
stronger association than the genotyped discovery variant
(P¼1.91108 and OR¼1.85 (95% CI¼1.49–2.29)). Both the
imputed SNPs info measure (level of certainty of imputation)
and average maximum posterior call were499%, indicating good
quality of the imputation.
3.4. Evaluation of NBEA region in the IHGC sample
In the IHGC migraine GWAS meta-analysis, rs1160720 showed
no association with migraine overall (P¼0.11, OR¼0.98, 95%
CI¼0.95–1.01), migraine without aura (P¼0.74, OR¼0.99, 95%
CI¼0.94–1.04), or migraine with aura (P¼0.02, OR¼0.93, 95%
CI¼0.88–0.99). None of the other examined top SNP yielded
signiﬁcant association with migraine in the IHGC sample (data
not shown).
Fig. 1. Quantile–Quantile plot (QQ-plot) of observed and expected P-values, -log
transformed. The genetic inﬂation factor (λ) was 1. The dashed horizontal line
indicates a P-value of 5108. The grey shading indicates a 95% Conﬁdence
Interval.
Fig. 2. Manhattan plot of results of logistical regression analyses. Chromosomes are pictured along the x-axis in alternating colors.  log10 P-values are plotted on y-axis. Red
line indicates genome wide signiﬁcance at 5108. A locus on chromosome 13 surpasses the threshold for genome wide signiﬁcance.
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4. Discussion
Here, we present the results of a GWAS on migraine in bipolar
disorder, culminating in a genome-wide signiﬁcant association
with the NBEA locus. The top SNP was rs1160720 (P-value
2.97108, OR¼1.82, 95% CI¼1.47–2.25), with several other SNPs
in linkage disequilibrium (LD) showing a trend for association,
including an imputed SNP with P-value of 1.91108.
Interestingly, our top hit, rs1160720, did not show any associa-
tion with migraine (IHGC sample in this study) nor bipolar
disorder itself (P¼0.19 in PGC meta-analysis, http://www.broad
institute.org/mpg/ricopili/). Thus, the only signiﬁcant result noted
in this study was that of NBEA and migraine among bipolar
disorder patients. These observations may suggest possible etio-
logical speciﬁcity of this gene to such a combined phenotype,
conﬁrming our initial hypothesis of co-morbid migraine in BPD
being a distinct syndrome with slightly different genetic risk
factors than common migraine itself or isolated bipolar disorder.
NBEA is located on chromosome 13q13, and encodes two
isoforms. It harbors another gene, MAB21L1, in intron 41 of the
long isoform, that contains a fragile site (FRA13A) (Tsang et al.,
2009). The top SNP of our analyses is located in a LD-region
surrounding intron 36 of the long isoform of NBEA. NBEA encodes
neurobeachin (NBEA), a BEACH (BEige And Chediak–Higashi)
scaffolding protein primarily expressed in the brain (Lauks et al.,
2012). Cellular studies show that NBEA is involved in trafﬁcking of
vesicles containing neurotransmitter receptors, speciﬁcally GABA
and glutamate receptors (Lauks et al., 2012; Nair et al., 2013). In
addition, it interacts with a glycine receptor in inhibitory neurons
(del Pino et al., 2011). Changes in NBEA function due to partial or
complete knockout of the gene cause functional and morphologi-
cal alterations in neuronal spines and synapses (Medrihan et al.,
2009; Niesmann et al., 2011). Nair et al. (2013) showed that
Nbea / neurons have lower level of glutamate- and GABA
receptors on their surface, and that these receptors accumulate
at the post-Golgi site where Nbea would normally be located. In
addition, NBEA has been linked to autism and autism symptoms
(Castermans et al., 2003; Nuytens et al., 2013; Smith et al., 2002).
Studies on MAB21L1 gene indicate a possible role in neurode-
velopmental disorders, probably due to expansion of CAG repeats,
which could also inﬂuence NBEA (Meira-Lima et al., 2001). How-
ever, the close proximity makes it difﬁcult to separate effects of
the two genes (Cullinane et al., 2013; Tsang et al., 2009). Moreover,
the identiﬁed associated region is also physically close to DCLK1, a
gene which has been implemented in neurodevelopment, vesicle
transport, verbal memory, schizophrenia and attention deﬁcit/
hyperactivity disorder (ADHD) (Håvik et al., 2012; Smith et al.,
2002). However, there is a recombination hot spot between NBEA
and DCLK1, and we found no LD between a previously reported
signiﬁcant SNP in DCLK1 and our top hit (r2¼0.001 and D0 ¼0.035).
Table 1
Top associated loci with P-value o1104.
Chr SNP Position Gene Gene function or previous gene association from the literature Allele* CEU freq OR† 95% CI‡ P-value
1 rs10875290 100626343 CDC14A Cell cycle control T 0.35 1.53 1.30–1.80 3.55E-07
1 rs1571346 110478611 Intergenic G 0.48 1.38 1.18–1.62 7.94E-05
1 rs6667692 182820193 C1orf21 No putative function C 0.39 0.71 0.61–0.84 4.01E-05
3 rs3860579 21539353 ZNF385D Among top hits in partial epilepsy GWAS
(Kasperaviciute et al., 2010) and GWAS on negative symptoms
in schizophrenia (Xu et al., 2013)
A 0.36 0.7 0.59–0.83 5.36E-05
3 rs10936719 173485820 FNDC3B Various non-psychiatric traits like height. G 0.52 0.7 0.59–0.83 2.09E-05
4 rs4832800 36033902 Intergenic A 0.21 0.65 0.52–0.81 8.90E-05
5 rs350033 40240372 Intergenic T 0.11 1.9 1.45–2.50 3.91E-06
5 rs17167531 99329060 Intergenic C 0.33 0.69 0.58–0.82 3.17E-05
6 rs1474618 18763549 Intergenic C 0.32 0.69 0.57–0.83 5.52E-05
6 rs4644033 67614614 Intergenic T 0.37 1.42 1.20–1.68 3.73E-05
7 rs2854843 45897660 IGFBP1 Binds Insuline-like growth factor (IGF) C 0.17 1.58 1.27–1.96 3.81E-05
7 rs6949094 136934899 DGKI Diacyl glycerol kinase, iota type. Associated
with dyslexia (Matsson et al., 2011), and schizophrenia
(Moskvina et al., 2008)
C 0.05 2.05 1.44–2.92 7.19E-05
7 rs2058448 150077753 Intergenic T 0.27 0.67 0.56–0.81 4.47E-05
9 rs1529191 101885729 ERP44 Regulation of serotonin
transporter (Freyaldenhoven et al., 2012)
A 0.45 0.72 0.61–0.85 9.41E-05
10 rs10904109 3886686 Intergenic G 0.00 2.51 1.62–3.86 2.99E-05
10 rs11016132 129908545 Intergenic G 0.05 0.38 0.24–0.61 4.68E-05
11 rs2344350 6281254 Intergenic T 0.16 0.59 0.46–0.77 5.64E-05
11 rs2682095 6393280 APBB1 APP binding protein, possibly regulating cell
cycle and transcription.
G 0.24 1.4 1.18–1.66 8.37E-05
12 rs11106592 91417726 Intergenic A 0.05 0.55 0.40–0.74 8.62E-05
12 rs6490045 114872013 Intergenic A 0.10 1.73 1.32–2.27 8.09E-05
13 rs1887894 20505600 LATS2 Mitosis regulating protein. A 0.26 1.43 1.19–1.70 6.98E-05
13 rs1160720 34784675 NBEA Involved in neuronal post-Golgi trafﬁcking,
including neurotransmitter receptors.
G 0.16 1.82 1.47–2.25 2.97E-08
14 rs2282031 89800696 PSMC1 Proteasome subunit, with chaperone-like activity.
Associated with formation of Lewy bodies Bedford et al., 2008.
C 0.32 0.69 0.59–0.83 3.77E-05
15 rs8026848 27361149 FAM189A1 No putative function G 0.24 1.45 1.20–1.75 9.04E-05
15 rs7168815 85238303 AGBL1 Variants associated with Fuchs cornea dystrophy. A 0.09 0.41 0.27–0.61 8.05E-05
20 rs41392045 13022330 SPTLC3 Subunit of SPT, catalyzing sphingolipid synthesis.
Trend in bipolar disorder with agressiveness/hostility
(Alliey-Rodriguez et al., 2011).
C 0.04 2.07 1.46–2.91 3.38E-05
20 rs4635580 40383245 PTPRT Possible role in signal transduction and cell adhesion in CNS. T 0.06 0.34 0.21–0.57 4.50E-05
22 rs6004447 23869631 KIAA1671 Decreased expression in thyroid cancer G 0.32 1.47 1.23–1.75 2.20E-05
23 rs5972211 30609088 GK Phosphorylates glycerol , initiating its metabolism. A 0.30 0.67 0.55–0.81 4.79E-05
n Tested allele in this study.
† OR¼Odds ratio.
‡ 95% CI¼95% Conﬁdence Interval.
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Thus, it is unlikely that these associations represent the same
signal.
Migraine aura is thought to be caused by cortical spreading
depression, a wave of neuronal depolarization or hyperexcitability
followed by a period of decreased neuronal activity(Cutrer and
Smith, 2013; Stuart et al., 2012). The exact cause of cortical
spreading depression is not known, but a disturbance of glutamate
homeostasis in the brain is thought to be involved (Ligthart et al.,
2011). Previous GWA studies in migraine have found an associa-
tion with genes of the glutamatergic system, including MTDH,
which in turn regulates SLC1A2, a major glutamate transporter in
the brain (Anttila et al., 2010; Ligthart et al., 2011). The glutamate
system is also associated with bipolar disorder through several
studies, such as genetic association, abnormal mRNA expression
and increased glutamate levels in magnetic resonance spectro-
scopy (Cherlyn et al., 2010; Gigante et al., 2012). Notably, Sklar
et al. (2008) found an association between bipolar disorder and
MYO5B, which encodes a vesicle transportation protein involved in
the trafﬁcking of glutamate receptors (Lisé et al., 2006). Based on
the knowledge that glutamate is important in both disorders
studied, it is striking that our top SNP is located in a gene with
such direct involvement in the glutamatergic system. Thus, we
may hypothesize that NBEA-caused disturbances of this system
might lead to the development of a speciﬁc bipolar disorder sub-
phenotype, represented by its co-occurrence with migraine.
5. Limitations
Our study should be viewed in the light of some limitations.
First it is based on self-reported migraine, while the gold standard
is a physician diagnosis. Nonetheless, Schürks et al. (2009) veriﬁed
doctor-diagnosed migraine in more than 87% of women with self-
reported migraine, indicating a high validity of such records.
Still, we must assume a certain level of phenotypic heterogeneity
in our sample, which affects both the power within our study and
the chances of replication in samples with stricter diagnostic
criteria, such as the IHGC. Second, we unfortunately did not have
access to bipolar co-morbidity information in the IHGC migraine
meta-analysis sample, and thus, could not test for a putative
interaction with bipolar diagnosis. The data however, clearly show
that the NBEA-locus is not associated with common migraine. The
similar allele frequency of rs1160720 across the samples without
the combination of bipolar disorder and migraine (Table 2) sup-
port the notion that NBEA is not a major risk factor for either
bipolar disorder or migraine, but that it is a risk factor for a speciﬁc
bipolar disorder phenotype, where co-morbid migraine is one of
the features. Such a hypothesis is in line with the epidemiological
ﬁndings of a more severe phenotype among bipolar patients with
migraine.
Third, although the results in the current study are at the whole
genome signiﬁcance level, we were not able to replicate our top
hit in the smaller GAIN sample. This could indicate that the true
effect size is considerably over-estimated in the TGEN sample (i.e.
“winner's curse”) and this would consequently lead to an over-
estimation of our power to replicate rs1160720 in GAIN sample.
Despite TGEN and GAIN being by far the largest published GWAS
collections of bipolar patients with information on co-morbid
migraine, they may be considered small compared to most GWA
studies performed to date and the divergent ﬁndings show that
much larger samples are needed. One could also be concerned
about the validity of the genotyping, however the QC, including
Hardy–Weinberg equilibrium tests in both cases and controls, and
the strong LD-structure with support from several other SNPs in
close vicinity does not support genotype error as a cause of false
Fig. 3. LocusZoom plot of the candidate region on chromosome 13. Imputed SNPs are shown as circles, directly genotyped SNPs as diamonds. The color scheme indicates
linkage disequilibrium (LD) structure across the region. The blue line indicates recombination rate. P-values are –log transformed. The top SNPs are in intronic regions of
neurobeachin (NBEA). Rs1160720 is marked by a purple diamond (P-value 2.97108, OR: 1.82, 95% CI: 1.47–2.25).
Table 2
Overview of alle frequencies of rs1160720.
Sample Minor allele frequency Sample size
TGEN bp migþ 0.218 460
TGEN bp mig 0.135 914
TGEN controls 0.163 479
GAIN bp migþ 0.167 283
GAIN bp mig 0.178 686
GAIN controls 0.184 1014
IHGC migþ 0.168 23285
IHGC mig 0.171 95425
HapMap CEU 0.155 113
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association. Furthermore, there might be clinical differences
between the samples, as they have been collected with slightly
different recruitment strategies.
6. Conclusion
We report a genome-wide signiﬁcant association between a
SNP in NBEA and risk of migraine among individuals with BPD. In
contrast, there was no association observed between this variant
and common migraine nor BPD itself. Thus, a shared genetic
component between these two disorders within a speciﬁc sub-
group of patients may be hypothesized. The likely involvement of
NBEA gene in both migraine and BPD highlights the role of the
glutamatergic system as a putative pathway leading to the devel-
opment of co-morbid migraine and BPD (Cherlyn et al., 2010;
Ligthart et al., 2011).
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